CLINICAL_TRIALS
trial_result
· 2016-03-25
Clinical Trial Update: Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia [Phase 1, Phase 2]
Summary
Clinical trial update indicates that the Phase 1/2 safety study of AKN-028 in Acute Myeloid Leukemia has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Akinion Pharmaceuticals AB | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: TERMINATED